WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009140587) PULMONARY DELIVERY OF A FLUOROQUINOLONE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/140587    International Application No.:    PCT/US2009/044116
Publication Date: 19.11.2009 International Filing Date: 15.05.2009
IPC:
A61K 9/00 (2006.01), A61K 31/496 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35 CH-4056 Basel (CH) (For All Designated States Except US).
WEERS, Jeffry [US/US]; (US) (For US Only).
TARARA, Thomas [US/US]; (US) (For US Only)
Inventors: WEERS, Jeffry; (US).
TARARA, Thomas; (US)
Agent: MANZARI, Oona, A.; Novartis Patent Department One Health Plaza Building 101 East Hanover, NJ 07936 (US)
Priority Data:
61/127,780 15.05.2008 US
Title (EN) PULMONARY DELIVERY OF A FLUOROQUINOLONE
(FR) ADMINISTRATION PULMONAIRE D'UNE FLUOROQUINOLONE
Abstract: front page image
(EN)A composition for pulmonary administration comprises a fluoroquinolone betaine, such as ciprofloxacin betaine, and an excipient. In one version, the particles have a mass median aerodynamic diameter from about 1 µm to about 5 µm, and the fluoroquinolone has a half life in the lungs of at least 1.5 hours. The composition is useful in treating an endobronchial infection, such as Pseudomonas aeruginosa, and is particularly useful in treating cystic fibrosis.
(FR)L'invention concerne une composition pour une administration pulmonaire qui comporte une fluoroquinolone bétaïne, telle que la ciprofloxacine bétaïne, et un excipient. Dans une version, les particules ont un diamètre aérodynamique moyen massique d'environ 1 µm à environ 5 µm, et la fluoroquinolone a une demi-vie dans les poumons d'au moins 1,5 heure. La composition, qui s'utilise dans le traitement d'une infection endobronchique, telle que par le Pseudomonas aeruginosa, est particulièrement utile dans le traitement de la mucoviscidose.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)